Tricyclic Pyrones, Inhibiting Amyloid-ß Aggregation and Improving Memory and Motor Functions in Alzheimer’s Disease Mice
Reference Number: 99-20
Inventors: Duy Hua
Researchers at Kansas State University (K-State) have created novel compounds called tricyclic pyrones (TP) that have been shown to decrease the aggregation of amyloid-ß plaques and soluble amyloid ? oligomers in Alzheimer’s Disease (AD) mouse (5XFAD) brain, and improve memory and motor functions in AD mice (APP/PS1). Moreover, the compound also restores axonal mitochondria trafficking of AD mice and enhances long-term potentiation. Increasing evidence suggests that alternation of amyloid precursor protein (APP) metabolism and fibrillation of amyloid-ß peptides (Aß, proteolytic products of APP) may be central pathogenetic events leading to Alzheimer’s disease (AD). (J. Molecular Neuroscience2002, 19, 57-61;Tetrahedron2003, 59, 4795-4803; J. Neurochem.2006, 98, 57-67; J. Neurochem.2009, 108, 1097-1108). The TP compounds also have excellent bioavailability and pharmacokinetic profile with low or undetected toxicity after one year treatment to mice.
These studies suggest that TP could provide a good candidate as a treatment of Alzheimer’s Disease.
The TP compounds not only enhance neurological and memory phenotypes, and restore mitochondrial axonal trafficking in AD mice, they also enhance memory. Hence improvement of memory in elderly may be achieved from this class of compounds.
- Potential treatment for Alzheimer’s Disease
- U.S. patent #7,935,726 issued on May 3, 2011.
Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.
Interested parties should contact:
Kansas State University Institute for Commercialization (KSU-IC)
2005 Research Park Circle Manhattan, KS 66502
Tel: 785-532-3900 Fax: 785-532-3909